Integrase resistance emergence with dolutegravir/lamivudine with prior HIV-1 suppression
Autor: | Boris Revollo, Laura Viñuela, Lorena de la Mora, Federico García, Marc Noguera-Julián, Mariona Parera, Roger Paredes, Josep M. Llibre |
---|---|
Rok vydání: | 2022 |
Předmět: |
Male
Pharmacology Microbiology (medical) Integrases Pyridones HIV Infections RNA-Directed DNA Polymerase Piperazines Infectious Diseases Lamivudine Drug Resistance Viral HIV Seropositivity Oxazines HIV-1 Leukocytes Mononuclear Humans Pharmacology (medical) HIV Integrase Inhibitors Viremia Heterocyclic Compounds 3-Ring |
Zdroj: | Journal of Antimicrobial Chemotherapy r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol instname |
ISSN: | 1460-2091 0305-7453 |
DOI: | 10.1093/jac/dkac082 |
Popis: | Objectives Integrase resistance has not been reported with co-formulated dolutegravir/lamivudine in clinical trials or real-life cohorts. We aim to report, to the best of our knowledge, the first case of selection of the key integrase mutation R263K in a subject treated with this regimen started as a switch strategy with undetectable plasma HIV-1 viraemia. Methods Clinical case report. Results A patient with long-term suppressed HIV-1 viraemia ( Conclusions This case illustrates that integrase resistance can emerge in patients treated with co-formulated dolutegravir/lamivudine and raises awareness of the need to carefully consider and monitor drug–drug interactions, even when regarded as having a low potential, in subjects treated with dolutegravir/lamivudine. |
Databáze: | OpenAIRE |
Externí odkaz: |